Gilead Announces Partial Clinical Hold For Magrolimab Studies In AML
Portfolio Pulse from Benzinga Newsdesk
Gilead Sciences has announced a partial clinical hold for its Magrolimab studies in Acute Myeloid Leukemia (AML). However, patients already enrolled may continue receiving the study medicine and studies in solid tumors remain unaffected.
August 21, 2023 | 12:31 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Gilead's Magrolimab studies in AML have been partially halted, potentially delaying the drug's development and approval. However, the impact may be mitigated as enrolled patients can continue treatment and other studies are unaffected.
The partial clinical hold on Gilead's Magrolimab studies could potentially delay the drug's development and approval, which could negatively impact Gilead's stock in the short term. However, the fact that enrolled patients can continue treatment and other studies are unaffected may mitigate this impact to some extent.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100